Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells

Basit Öğe Kaydı
dc.authoridÖzünal, Zeynep güneş/0000-0002-3060-1507en_US
dc.authoridkayalı, damla/0000-0003-0674-090Xen_US
dc.authoridAktas, Ranan/0000-0002-4474-7371en_US
dc.authoridDönmez Çakıl, Yaprak/0000-0002-4605-1167en_US
dc.contributor.authorÇakıl, Yaprak Dönmez
dc.contributor.authorGüneş Özünal, Zeynep
dc.contributor.authorKayali, Damla Gokceoğlu
dc.contributor.authorAktas, Ranan Gülhan
dc.contributor.authorSaglam, Esra
dc.date.accessioned2024-07-12T21:37:45Z
dc.date.available2024-07-12T21:37:45Z
dc.date.issued2022en_US
dc.department[Belirlenecek]en_US
dc.description.abstractHepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib is the first approved drug for the treatment of advanced HCC. Depression is frequent in cancer patients. Moreover, sorafenib might exert depression as an adverse drug reaction and paroxetine, a selective serotonin reuptake inhibitor, is a recommended pharmacotherapy. This study aimed to investigate the potential synergistic effects of paroxetine and sorafenib on HepG2 cell proliferation and death. Paroxetine and sorafenib were administered to HepG2 cells as singleagents or in combination. Cell viability was determined with XTT cell viability assay. Cellular apoptosis and DNA content were assessed by flow cytometry. The expression of anti-apoptotic Bcl-2 was examined by immunofluorescence confocal microscopy. A lower dose of sorafenib was found to be required to inhibit cell proliferation when in combination with paroxetine. Similarly, the coadministration enhanced cellular apoptosis and resulted in cell cycle arrest. Confocal imaging revealed a remarkably lower cell density and increased expression of Bcl2 following combined treatment of paroxetine with sorafenib. To our knowledge, this is the first study demonstrating the synergistic effect of paroxetine and sorafenib in HCC and might provide a potentially promising therapeutic strategy.en_US
dc.identifier.doi10.1590/s2175-97902022e201148
dc.identifier.issn1984-8250
dc.identifier.issn2175-9790
dc.identifier.scopus2-s2.0-85145916193en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1590/s2175-97902022e201148
dc.identifier.urihttps://hdl.handle.net/20.500.12415/6924
dc.identifier.volume58en_US
dc.identifier.wosWOS:000922191100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherUniv Sao Paulo, Conjunto Quimicasen_US
dc.relation.ispartofBrazilian Journal of Pharmaceutical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY04266
dc.subjectParoxetineen_US
dc.subjectSorafeniben_US
dc.subjectPharmacotherapyen_US
dc.titleAnti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cellsen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu